Analyst: Biotech Stock to Drop Now

ACOR shares are down on restructuring plans and weak drug sales

Managing Editor
Oct 24, 2019 at 10:19 AM
facebook twitter linkedin


Shares of Acorda Therapeutics Inc (NASDAQ:ACOR) are plunging this morning, already down 13.9% to trade at $2.33. Acorda issued a double-whammy last night, sharing its corporate restructuring plan -- which includes a 25% cut to its workforce -- and unveiling lackluster third-quarter sales of Inbrija, its Parkinson's drug. As such, ACOR was slapped with a pair of bearish notes from analysts.

J.P. Morgan Securities analyst Cory Kasimov downgraded ACOR stock to "underweight" from "neutral," stating, "We simply don't see a near-term fix for [Inbrija] or [this] company," and warning that the pharma concern's "path forward could become increasingly difficult." Meanwhile, Wedbush trimmed its price target to $2.78 from $3. From a broader perspective, seven of eight covering brokerage firms issued a "hold" recommendation coming into today, with one offering up a "strong buy."

On the charts, Acorda Therapeutics stock has had a rough go, shedding 86% over the past 12 months alone. The descending 40-day trendline has been overhead resistance for the shares in 2019, capping multiple breakout attempts since January. What's more, ACOR shares touched a 13-year low of $2.27 on Oct. 14, and matched that low in intraday trading this morning.

Short interest on ACOR has been plunging, down 19.1% during the past two reporting periods. However, these bearish bets still account for more than 27% of the stock's total available float.
 

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!